Pancreatic cancer patients who participate in clinical research have better outcomes. Every treatment available today was approved through a clinical trial. PanCAN strongly recommends clinical trials at diagnosis and during every treatment decision.
PanCAN maintains the most comprehensive and up-to-date database of pancreatic cancer clinical trials available in the United States. There are two ways you can access this free information to receive available clinical trials that might be right for you:
Clinical Trial Finder
Frequently Asked Questions
What is PanCAN’s Precision Promise adaptive clinical trial?
Precision Promise is an adaptive clinical trial sponsored by PanCAN. The novel clinical trial platform efficiently tests new therapies for their effectiveness in treating patients with pancreatic cancer.
PanCAN brings together key stakeholders – investigators, clinicians, industry and pancreatic cancer thought-leaders – to make this historic initiative possible with the goal to bring new treatment options to patients.
Who can enroll in PanCAN’s Precision Promise adaptive clinical trial?
If a patient is interested in enrolling in PanCAN’s Precision Promise adaptive clinical trial, they will need to consult with their oncologist/healthcare team. A patient’s treating physician can determine if they are eligible to enroll. A patient would have to go to one of the 14 Precision Promise sites to enroll in the trial.
The trial will enroll patients with metastatic pancreatic cancer who have either received no treatment in the metastatic setting (first line), or who have only received one prior treatment for their cancer in the metastatic setting (second line).
What treatment options will be included in PanCAN’s Precision Promise adaptive clinical trial?
Multiple treatment arms will be simultaneously tested through PanCAN’s Precision Promise adaptive clinical trial and compared to multiple standard of care therapies. In addition to investigating potential new treatment therapies, Precision Promise will also be investigating supportive care measures.
What is supportive care?
Supportive care involves treatments given to manage symptoms and side effects of a disease. PanCAN’s Precision Promise adaptive clinical trial will include investigational supportive care measures designed to learn more about factors that contribute to a patient’s quality of life like pain management and patient activity.
Where is PanCAN’s Precision Promise adaptive clinical trial located, and when will the sites open?
There are 14 initial Clinical Trial Consortium sites across the United States. The sites will start opening in early 2020, with the majority expected to open throughout the year. The Clinical Trial Consortium page will continue to be updated as sites open.
For additional questions about clinical trials or other topics related to a pancreatic cancer diagnosis, contact PanCAN’s Patient Central or ask your doctor to contact PanCAN’s Healthcare Professional Services.
Contact Patient Central
PRECISION PROMISESM is a service mark of Pancreatic Cancer Action Network, Inc.